“Unleashing Innovation: DZD Scores Major Win for Safer Fecal Microbiota Transplants with SBIR Funding
BOSTON, Aug. 29, 2023 /PRNewswire/ — Brace yourself for a game-changing announcement from Day Zero Diagnostics (DZD) Inc., the trailblazing force in infectious disease diagnostics. The spotlight is on as DZD takes center stage with a triumphant Phase I Small Business Innovation Research (SBIR) award from the esteemed National Institute of Allergies and Infectious Disease (NIAID), under the wing of the revered National Institutes of Health (NIH).
Hold onto your seat as we unveil the grand plan: epiXact® FMT. This groundbreaking pharmacovigilance assay isn’t just a solution; it’s a new era in safety and efficacy for fecal microbiota transplant (FMT) clinical trials. With this funding boost, DZD is on a mission to elevate the standards of patient care and revolutionize the world of medical innovation.
Prepare for a paradigm shift in the world of medical breakthroughs! Day Zero Diagnostics Inc. has just secured a Phase I Small Business Innovation Research award from the prestigious NIAID, a cornerstone of the legendary NIH. This marks the dawn of a new era in medical innovation that promises to redefine patient care and infection control.
Imagine a groundbreaking therapy that doesn’t just treat diseases, but transforms lives. Fecal microbiota transplantation (FMT), the vanguard of medical advancement, ushers in a world where healthy microbial communities from donors dance their way into patients’ gut health. It’s a cutting-edge approach recently greenlit for recurrent Clostridium difficile infections (CDI), backed by a symphony of clinical research.
But the story doesn’t end there. Even with stringent screening, there’s a tale of caution in recent cases – a potential transmission of pathogens. In a scientific thriller worthy of the New England Journal of Medicine, enter DZD’s epiXact®. Through this innovative marvel, high-resolution genomic analysis uncovered a hidden truth: pathogenic bacteria hitched a ride from donor to patient, leading to an unforeseen demise and sparking an FDA safety alert.
Cue Dr. Mohamad Sater, the mastermind behind this quest for safety. With unwavering determination, he notes, “Microbiota transplant safety hinges on vigilant donor screening and lightning-fast transmission detection.” Enter a visionary pipeline of strain detection, armed with complex metagenomic sample analysis and prior triumphs. This isn’t just science; it’s a life-saving narrative that propels personalized medicine into the spotlight.
As the symphony of innovation plays on, Jong Lee, the visionary CEO and Co-founder of DZD, shares his exhilaration. “With the NIH’s support, we’re not just expanding our epiXact® services; we’re shaping the destiny of infectious disease diagnostics and infection control.”
The tale is driven by an enchanting force – the SBIR grant, backed by the illustrious National Institute of Allergy and Infectious Diseases. The curtain rises on a journey that promises to rewrite the rules of medicine. This, my friends, is a story where innovation takes center stage, orchestrated by Day Zero Diagnostics, for the sake of humanity’s well-being. The revolution has begun.
About Day Zero Diagnostics
From Boston’s Heart: Day Zero Diagnostics, Inc. Unveils a New Frontier in Fighting Antibiotic Resistance
In the heart of Boston, a new chapter in the fight against antibiotic resistance is being written. Meet Day Zero Diagnostics, Inc. – not just a company, but a trailblazing force that’s rewriting the rules of infectious disease diagnostics. Armed with whole-genome sequencing and machine learning, they’re not just tackling diseases; they’re revolutionizing the game.
Their mission? Nothing short of changing the course of how the world confronts infectious diseases. Picture a world where species and antibiotic resistance profiles of severe infections are unraveled with lightning speed, right from a clinical sample. And no, we’re not talking about the traditional methods; Day Zero is changing the narrative by skipping the culture step.
But that’s not all. Imagine a treasure trove of lab services that harness the power of whole-genome sequencing. With technology that’s exclusive to them and databases curated to perfection, Day Zero isn’t just managing healthcare-associated infection outbreaks; they’re rewriting the playbook for clinical decisions that make an impact.
Back in 2016, this journey began with a team that reads like a who’s who of brilliance – clinicians and scientists from Harvard University and Massachusetts General Hospital. Their brainchild, Day Zero Diagnostics, has become a beacon of innovation. The honors have poured in, from recognition by the likes of CARB-X, UCSF Health, American Association of Clinical Chemistry, MedTech Innovator, TedMed Hive, Xconomy, HealthTech Arkansas, to the prestigious MassChallenge HealthTech.
So, buckle up. This isn’t just a company; it’s a movement. This isn’t just innovation; it’s a revolution. Day Zero Diagnostics, Inc. isn’t just pioneering; they’re leading the charge into a future where infectious diseases meet their match.